References analysis of the Wikipedia article "Vortioksetiini" in the Finnish version

cambridge.org

Stephen M. Stahl: Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectrums, 2015-10, 20. vsk, nro 5, s. 455–459. doi:10.1017/S1092852915000346 ISSN 1092-8529 Artikkelin verkkoversio. (englanti)

doi.org

dx.doi.org

Riccardo Bortoletto, Elena Puttini, Leonardo Zoccante, Marco Colizzi: Vortioxetine Add-On to Methylphenidate for the Treatment of Symptoms of Sickness Behavior in Attention-Deficit Hyperactivity Disorder: Report of Two Cases. Reports, 2021-12, 4. vsk, nro 4, s. 30. doi:10.3390/reports4040030 ISSN 2571-841X Artikkelin verkkoversio. (englanti)

Michael Cronquist Christensen, Simon Nitschky Schmidt, Iria Grande: Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study. Journal of Affective Disorders, 1.10.2023, 338. vsk, s. 423–431. PubMed:37315590 doi:10.1016/j.jad.2023.06.024 ISSN 1573-2517 Artikkelin verkkoversio.

Grace Chen, Astrid-Maria Højer, Johan Areberg, George Nomikos: Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clinical Pharmacokinetics, 2018-06, 57. vsk, nro 6, s. 673–686. PubMed:29189941 doi:10.1007/s40262-017-0612-7 ISSN 1179-1926 Artikkelin verkkoversio.

Andrea Fagiolini, Ioana Florea, Henrik Loft, Michael Cronquist Christensen: Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. Journal of Affective Disorders, 15.3.2021, 283. vsk, s. 472–479. PubMed:33516560 doi:10.1016/j.jad.2020.11.106 ISSN 1573-2517 Artikkelin verkkoversio.

Kumi Matsuno, Koki Nakamura, Yutaka Aritomi, Akira Nishimura: Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Adults. Clinical Pharmacology in Drug Development, 2018, 7. vsk, nro 3, s. 319–331. PubMed:28941196 doi:10.1002/cpdd.381 ISSN 2160-763X Artikkelin verkkoversio.

Eduard Vieta, Ioana Florea, Simon Nitschky Schmidt, Johan Areberg, Anders Ettrup: Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. International Clinical Psychopharmacology, 2019-7, 34. vsk, nro 4, s. 153–160. PubMed:31094901 doi:10.1097/YIC.0000000000000271 ISSN 0268-1315 Artikkelin verkkoversio.

Chantal Moret, Mike Briley: The importance of norepinephrine in depression. Neuropsychiatric Disease and Treatment, 2011, 7. vsk, nro Suppl 1, s. 9–13. PubMed:21750623 doi:10.2147/NDT.S19619 ISSN 1176-6328 Artikkelin verkkoversio.

Amy F. T. Arnsten, C. Huie Lin, Christopher H. Van Dyck, Kelly J. Stanhope: The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiology of Aging, 1.1.1997, 18. vsk, nro 1, s. 21–28. doi:10.1016/S0197-4580(96)00162-5 ISSN 0197-4580 Artikkelin verkkoversio.

Tomkins DM, Higgins GA, Sellers EM: Low doses of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake. Psychopharmacology (Berl)., 1994, 115. vsk, nro 1–2, s. 173–9. PubMed:7862892 doi:10.1007/BF02244769

Müller CP, Carey RJ, Huston JP, De Souza Silva MA: Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors. Prog Neurobiol., 2007, 81. vsk, nro 3, s. 133–78. PubMed:17316955 doi:10.1016/j.pneurobio.2007.01.001

Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Müller CP, Huston JP: Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects. Brain Res., 2005, 1034. vsk, nro 1–2, s. 162–71. PubMed:15713268 doi:10.1016/j.brainres.2004.12.012

de Boer SF, Koolhaas JM: 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol., 2005, 526. vsk, nro 1–3, s. 125–39. PubMed:16310183 doi:10.1016/j.ejphar.2005.09.065

Parks CL, Robinson PS, Sibille E, Shenk T, Toth M: Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci U S A., 1998, 195. vsk, nro 18, s. 10734–9. PubMed:9724773 PubMed Central:27964 doi:10.1073/pnas.95.18.10734

Ebenezer IS, Arkle MJ, Tite RM: 8-Hydroxy-2-(di-n-propylamino)-tetralin inhibits food intake in fasted rats by an action at 5-HT1A receptors. Methods Find Exp Clin Pharmacol., 1998, 29. vsk, nro 4, s. 269–72. PubMed:17609739 doi:10.1358/mf.2007.29.4.1075362

Wouters W, Tulp MT, Bevan P: Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors. Eur J Pharmacol., 1998, 149. vsk, nro 3, s. 213–23. PubMed:2842163 doi:10.1016/0014-2999(88)90651-6

Horiuchi J, McDowall LM, Dampney RA: Role of 5-HT(1A) receptors in the lower brainstem on the cardiovascular response to dorsomedial hypothalamus activation. Auton Neurosci., 2008, 142. vsk, nro 1–2, s. 71–6. PubMed:18667366 doi:10.1016/j.autneu.2008.06.004

Nalivaiko E, Ootsuka Y, Blessing WW.: Activation of 5-HT1A receptors in the medullary raphe reduces cardiovascular changes elicited by acute psychological and inflammatory stresses in rabbits. Am J Physiol Regul Integr Comp Physiol., 2005, 289. vsk, nro 2, s. R596–R604. PubMed:15802554 doi:10.1152/ajpregu.00845.2004

Lucot JB.: Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin. Eur J Pharmacol., 1994, 253. vsk, nro 1–2, s. 53–60. PubMed:8013549 doi:10.1016/0014-2999(94)90756-0

Winstanley CA, Theobald DE, Dalley JW, Robbins TW.: Interactions between serotonin and dopamine in the control of impulsive choice in rats: therapeutic implications for impulse control disorders. Neuropsychopharmacology., 2005, 30. vsk, nro 4, s. 669–682. PubMed:15688093 doi:10.1038/sj.npp.1300610

Ogren SO, Eriksson TM, Elvander-Tottie E, D'Addario C, Ekström JC, Svenningsson P, Meister B, Kehr J, Stiedl O: The role of 5-HT(1A) receptors in learning and memory. Behav Brain Res., 2008, 195. vsk, nro 1, s. 54–77. PubMed:18394726 doi:10.1016/j.bbr.2008.02.023

Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, Ando T, Inoue M, Maeda J, Suzuki K: Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am J Psychiatry, 2003, 160. vsk, nro 2, s. 334–40. PubMed:12562581 doi:10.1176/appi.ajp.160.2.334

Kennett GA, Dourish CT, Curzon G: Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol., 1987, 134. vsk, nro 3, s. 265–74. PubMed:2883013 doi:10.1016/0014-2999(87)90357-8

Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC.: Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain. Pharmacology., 2003, 67. vsk, nro 4, s. 182–194. PubMed:12595749 doi:10.1159/000068404

Millan MJ, Perrin-Monneyron S: Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors. Eur J Pharmacol., 1997, 321. vsk, nro 3, s. 11–3. PubMed:9085055 doi:10.1016/S0014-2999(97)00050-2

Prow MR, Martin KF, Heal DJ: 8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation. Eur J Pharmacol., 1996, 317. vsk, nro 1, s. 21–8. PubMed:8982715 doi:10.1016/S0014-2999(96)00693-0

Meyer LC, Fuller A, Mitchell D: Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 2006, 290. vsk, nro 2, s. R405–13. PubMed:16166206 doi:10.1152/ajpregu.00440.2005

Popova NK, Amstislavskaya TG: Involvement of the 5-HT(1A) and 5-HT(1B) serotonergic receptor subtypes in sexual arousal in male mice. Psychoneuroendocrinology, 2002, 27. vsk, nro 5, s. 609–18. PubMed:11965359 doi:10.1016/S0306-4530(01)00097-X

Monti JM, Jantos H: Dose-dependent effects of the 5-HT1A receptor agonist 8-OH-DPAT on sleep and wakefulness in the rat. J Sleep Res., 1992, 1. vsk, nro 3, s. 169–175. PubMed:10607047 doi:10.1111/j.1365-2869.1992.tb00033.x

Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS: A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience, 2007, 146. vsk, nro 2, s. 509–14. PubMed:17383105 doi:10.1016/j.neuroscience.2007.02.032

Gudelsky GA, Koenig JI, Meltzer HY: Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology, 1986, 25. vsk, nro 12, s. 1307–13. PubMed:2951611 doi:10.1016/0028-3908(86)90101-2

Ootsuka Y, Blessing WW.: Activation of 5-HT1A receptors in rostral medullary raphé inhibits cutaneous vasoconstriction elicited by cold exposure in rabbits. Brain Res., 2006, 1073-1074. vsk, s. 252–61. PubMed:16455061 doi:10.1016/j.brainres.2005.12.031

Harrison AA, Parsons LH, Koob GF, Markou A: RU 24969, a 5-HT1A/1B agonist, elevates brain stimulation reward thresholds: an effect reversed by GR 127935, a 5-HT1B/1D antagonist. Psychopharmacology (Berl)., 1999, 141. vsk, nro 3, s. 242–50. PubMed:10027505 doi:10.1007/s002130050831

Chojnacka-Wójcik E, Klodzinska A, Tatarczynska E: The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action. J Pharm Pharmacol., 2005, 57. vsk, nro 2, s. 253–7. PubMed:15720791 doi:10.1211/0022357055399

Lin D, Parsons LH: Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-maze. Pharmacol Biochem Behav., 2002, 71. vsk, nro 4, s. 581–7. PubMed:11888549 doi:10.1016/S0091-3057(01)00712-2

Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-Wójcik E: Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression. Behav Pharmacol., 2004, 15. vsk, nro 8, s. 523–34. PubMed:15577451 doi:10.1097/00008877-200412000-00001

Eriksson TM, Madjid N, Elvander-Tottie E, Stiedl O, Svenningsson P, Ogren SO: Blockade of 5-HT 1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission. Neuropharmacology, 2008, 54. vsk, nro 7, s. 1041–50. PubMed:18394658 doi:10.1016/j.neuropharm.2008.02.007

Amital D, Fostick L, Sasson Y, Kindler S, Amital H, Zohar J: Anxiogenic effects of Sumatriptan in panic disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol., 2005, 15. vsk, nro 3, s. 279–82. PubMed:15820416 doi:10.1016/j.euroneuro.2004.12.002

Feuerstein TJ, Hüring H, van Velthoven V, Lücking CH, Landwehrmeyer GB: 5-HT1D-like receptors inhibit the release of endogenously formed [3H]GABA in human, but not in rabbit, neocortex. Neurosci Lett., 1996, 209. vsk, nro 3, s. 210–4. PubMed:8736648 doi:10.1016/0304-3940(96)12637-9

Pitsikas N, Brambilla A, Borsini F.: Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task. Pharmacol Biochem Behav., 1994, 47. vsk, nro 1, s. 95–99. PubMed:8115433 doi:10.1016/0091-3057(94)90116-3

Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG: 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biological Psychiatry, 2005, 58. vsk, nro 10, s. 831–7. PubMed:16018977 doi:10.1016/j.biopsych.2005.05.012

Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczynska E: Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology, 2006, 51. vsk, nro 3, s. 578–86. PubMed:16828124 doi:10.1016/j.neuropharm.2006.04.017

Gasbarri A, Cifariello A, Pompili A, Meneses A: Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat. Behavioural Brain Research, 2008, 195. vsk, nro 1, s. 164–70. PubMed:18308404 doi:10.1016/j.bbr.2007.12.020

Liy-Salmeron G, Meneses A: Effects of 5-HT drugs in prefrontal cortex during memory formation and the ketamine amnesia-model. Hippocampus, 2008, 18. vsk, nro 9, s. 965–74. PubMed:18570192 doi:10.1002/hipo.20459

Meyer LC, Fuller A, Mitchell D: Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats. Am J Physiol Regul Integr Comp Physiol., 2006, 290. vsk, nro 2, s. 405–13. PubMed:16166206 doi:10.1152/ajpregu.00440.2005

Bonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, Galici R, Miller K, Atack J, Lovenberg TW, Dugovic C: Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther., 2007, 321. vsk, nro 2, s. 690–8. PubMed:17314195 doi:10.1124/jpet.107.119404

Thomas DR, Melotto S, Massagrande M, Gribble AD, Jeffrey P, Stevens AJ, Deeks NJ, Eddershaw PJ, Fenwick SH, Riley G, Stean T, Scott CM, Hill MJ, Middlemiss DN, Hagan JJ, Price GW, Forbes IT: SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. Br J Pharmacol., 2003, 139. vsk, nro 4, s. 705–14. PubMed:12812993 PubMed Central:1573887 doi:10.1038/sj.bjp.0705290

Michael Cronquist Christensen, Simon Schmidt, Iria Grande: Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study. Journal of Psychopharmacology (Oxford, England), 2022-05, 36. vsk, nro 5, s. 566–577. PubMed:35499104 doi:10.1177/02698811221090627 ISSN 1461-7285 Artikkelin verkkoversio.

Chi-Un Pae, Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A. Patkar, Praksh S. Masand, Alessandro Serretti: Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. Journal of Psychiatric Research, 2015-05, 64. vsk, s. 88–98. PubMed:25851751 doi:10.1016/j.jpsychires.2015.02.017 ISSN 1879-1379 Artikkelin verkkoversio.

Joseph Biederman, Annika Lindsten, Lasse B. Sluth, Maria Louise Petersen, Anders Ettrup, Hanne-Lise F. Eriksen, Maurizio Fava: Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. Journal of Psychopharmacology (Oxford, England), 2019-04, 33. vsk, nro 4, s. 511–521. PubMed:30843450 doi:10.1177/0269881119832538 ISSN 1461-7285 Artikkelin verkkoversio.

Theresa Coles, Cheryl Coon, Carla DeMuro, Lori McLeod, Ari Gnanasakthy: Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment, 2014, 10. vsk, s. 887. PubMed:24899807 doi:10.2147/NDT.S55220 Artikkelin verkkoversio. (englanti)

Nasriya A. Witt, Benita Lee, Kaylee Ghent, Wynne Q. Zhang, Alan L. Pehrson, Connie Sánchez, Georgianna G. Gould: Vortioxetine Reduces Marble Burying but Only Transiently Enhances Social Interaction Preference in Adult Male BTBR T+Itpr3tf/J Mice. ACS chemical neuroscience, 16.10.2019, 10. vsk, nro 10, s. 4319–4327. PubMed:31468969 doi:10.1021/acschemneuro.9b00386 ISSN 1948-7193 Artikkelin verkkoversio.

Mohammad Nizam Uddin, Yunyi Yao, Kevin Manley, David A. Lawrence: Development, phenotypes of immune cells in BTBR T+Itpr3tf/J mice. Cellular Immunology, 2020-12, 358. vsk, s. 104223. PubMed:33137646 doi:10.1016/j.cellimm.2020.104223 ISSN 1090-2163 Artikkelin verkkoversio.

A. Alcántara Montero, S. R. Pacheco de Vasconcelos: Role of vortioxetine in the treatment of neuropathic pain. Revista Espanola De Anestesiologia Y Reanimacion, 2022-12, 69. vsk, nro 10, s. 640–648. PubMed:36241510 doi:10.1016/j.redare.2022.09.003 ISSN 2341-1929 Artikkelin verkkoversio.

Anna Rita Zuena, Daniela Maftei, Giovanni Sebastiano Alemà, Francesca Dal Moro, Roberta Lattanzi, Paola Casolini, Ferdinando Nicoletti: Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Molecular Pain, 2018, 14. vsk, s. 1744806918808987. PubMed:30289053 doi:10.1177/1744806918808987 ISSN 1744-8069 Artikkelin verkkoversio.

Liebowitz MR, Careri J, Blatt K, Draine A, Morita J, Moran M, Hanover R: Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder. Depression and Anxiety, December 2017, 34. vsk, nro 12, s. 1164–1172. PubMed:29166552 doi:10.1002/da.22702 S2CID:37489812

Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. Journal of Medicinal Chemistry, May 2011, 54. vsk, nro 9, s. 3206–3221. PubMed:21486038 doi:10.1021/jm101459g

mdpi.com

nih.gov

pubmed.ncbi.nlm.nih.gov

Ewelina Dziwota, Marcin Olajossy: VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES. Acta Poloniae Pharmaceutica, 2016-11, 73. vsk, nro 6, s. 1433–1437. PubMed:29634095 ISSN 0001-6837 Artikkelin verkkoversio.

Andrew D’Agostino, Clayton D. English, Jose A. Rey: Vortioxetine (Brintellix): A New Serotonergic Antidepressant. Pharmacy and Therapeutics, 2015-1, 40. vsk, nro 1, s. 36–40. PubMed:25628505 ISSN 1052-1372 Artikkelin verkkoversio.

McCreary AC, Bankson MG, Cunningham KA: Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. J Pharmacol Exp Ther., 1999, 290. vsk, nro 3, s. 965–73. PubMed:10454466

ncbi.nlm.nih.gov

Vortioxetine. Bethesda (MD): National Institute of Child Health and Human Development, 2006. Teoksen verkkoversio (viitattu 12.3.2024).

Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME: A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of lu aa21004 in adults with major depressive disorder". European neuropsychopharmacology, s. 847–57. (doi:10.1016/j.euroneuro.2012.07.012. PMID 22898365) European neuropsychopharmacology.

Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV: Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States, s. 858–66. (doi:10.1016/j.euroneuro.2012.07.011 . PMID 22901736 .) European neuropsychopharmacology.

A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder., s. 68: 49–59. (doi:10.1111/ijcp.12328. PMID 24341301) Int J Clin Pract, Tammikuu 2014.

dailymed.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

worldcat.org

Vortioksetiini (Finnish Wikipedia)

cambridge.org

doi.org

dx.doi.org

drugs.com

europa.eu

ema.europa.eu

fda.gov

fimea.fi

spc.fimea.fi

firstwordpharma.com

laakeinfo.fi

mdpi.com

medyinfo.com

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pharmacafennica.fi

sciencedirect.com

semanticscholar.org

api.semanticscholar.org

springer.com

adisinsight.springer.com

statnews.com

terveyskirjasto.fi

web.archive.org

webmd.com

worldcat.org